Antibody Drug Conjugates Market
Global Antibody Drug Conjugates Market By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, and Others), By Technology (Cleavable Linker and Non-cleavable Linker) - Global Industry Share, Growth, Competitive Analysis and Forecast Period 2021-2027 Update Available - Forecast 2024-2030
The global antibody drug conjugate market is projected to register significant growth during the forecast period. Antibody-drug conjugates aim and eliminate only the cancerous cells and don’t harm the healthy cells, unlike chemotherapy, in which, both the cells are damaged. The antibody-drug conjugates are complex molecules that are composed of antibodies associated with an (anticancer) biologically active cytotoxic payload drug. An anticancer drug is associated with an antibody that mainly targets an attack (a protein that is only found in the tumor cells) that is a tumor protein.
As the number of antibody-drug conjugates used in the manufacturing of drugs and healthcare treatment expands, so does the pressure to strengthen their advancements, driving superior production techniques and supply chain innovations. A majority of pharmaceuticals are involved in R&D activities to innovate and develop antibody-drug conjugates, which is likely to stroke the growth of the market. The ability to distinguish between healthy and affected tissue is also one of the key factors that are anticipated to propel the growth of this market in near future.
Moreover, the increasing prevalence of cancer across the globe is pushing the demand for antibody-drug conjugates. For instance, according to the Leukemia and Lymphoma Society in 2020, an estimated 1,297,027 people in the US are either living with or are in remission from, leukemia, lymphoma, or myeloma. Availability of a large product pipeline and increasing trend of cost-effective and quality cancer treatment is driving the growth of antibody-drug conjugates market across the globe. The high cost associated with antibody-drug conjugates is one of the major factors that is hindering market growth.
Segmental Outlook
The global antibody drug conjugates market is segmented on the basis of application and technology. On the basis of application, the market is segmented into blood cancer, breast cancer, ovarian cancer, lung cancer, others. Among these, breast cancer dominated the market owing to the factors, such as the high prevalence of breast cancer on a global scale and the commercial availability of Kadcyla in most of the major regions. Further, on the basis of technology, the market is sub-divided into cleavable linkers, non-cleavable linkers.
Global Antibody Drug Conjugates Market Share by Application, 2020 (%)
Regional Outlooks
On the basis of geography, the market is divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America contributes a significant share in the global antibody-drug conjugate market, owing to the presence of major market players in the region, such as Seattle Genetics, Inc. Moreover, factors such as the presence of well-established healthcare infrastructure and supportive government initiatives are likely to boost the market growth in North America.
The Asia-Pacific market covers the analysis of China, India, Japan, and the Rest of Asia-Pacific. Availability of a large product pipeline and increasing trend of cost-effective and quality cancer treatment are some of the major factors that are driving the growth of the antibody-drug conjugates market. Moreover, the increasing prevalence of cancer is pushing the demand for antibody-drug conjugates.
Market Players Outlook
Key players of the antibody drug conjugates market include AbbVie Inc., Astellas Pharma Inc., Bayer AG, Celldex Therapeutics, Inc., Creative Biolabs, Inc., ImmunoGen, Inc., Lonza Group, Pfizer Inc., Seattle Genetics, Inc., and others. In order to survive in the market, these players adopt different marketing strategies such as a merger, acquisitions, product launch, and geographical expansion. For instance, in May 2019, Zymeworks entered into a licensing agreement with Iconic Therapeutics that grant non-exclusive rights of antibody-drug conjugate, ZymeLink for the development of ICON-2 for cancer.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global antibody drug conjugates market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Antibody Drug Conjugates Market
• Recovery Scenario of Global Antibody Drug Conjugates Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Antibody Drug Conjugates Market by Application
5.1.1. Blood Cancer
5.1.2. Breast Cancer
5.1.3. Ovarian Cancer
5.1.4. Lung Cancer
5.1.5. Others (Brain Tumor and Cervical Cancer)
5.2. Antibody Drug Conjugates Market by Technology
5.2.1. Cleavable Linker
5.2.2. Non-cleavable Linker
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AbbVie Inc.
7.2. Astellas Pharma Inc.
7.3. Bayer AG
7.4. Celldex Therapeutics, Inc.
7.5. Creative Biolabs, Inc.
7.6. Genentech, Inc.
7.7. Heidelberg Pharma AG
7.8. ImmunoGen, Inc.
7.9. Immunomedics, Inc.
7.10. Lonza Group
7.11. Mersana Therapeutics, Inc.
7.12. Oxford BioTherapeutics Ltd.
7.13. Pfizer Inc.
7.14. Progenics Pharmaceuticals Inc.
7.15. Seattle Genetics, Inc.
7.16. Sorrento Therapeutics, Inc.
7.17. Synthon Holding B.V.
7.18. Takeda Pharmaceutical Co. Ltd.
1. GLOBAL ANTIBODY DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
2. GLOBAL ANTIBODY DRUG CONJUGATES MARKET BY APPLICATION, 2020-2027 ($ MILLION)
3. GLOBAL ANTIBODY DRUG CONJUGATES FOR BLOOD CANCER MARKET BY REGION, 2020-2027 ($ MILLION)
4. GLOBAL ANTIBODY DRUG CONJUGATES FOR BREAST CANCER MARKET BY REGION, 2020-2027 ($ MILLION)
5. GLOBAL ANTIBODY DRUG CONJUGATES FOR OVARIAN CANCER MARKET BY REGION, 2020-2027 ($ MILLION)
6. GLOBAL ANTIBODY DRUG CONJUGATES FOR LUNG CANCER MARKET BY REGION, 2020-2027 ($ MILLION)
7. GLOBAL ANTIBODY DRUG CONJUGATES FOR OTHER APPLICATION MARKET BY REGION, 2020-2027 ($ MILLION)
8. GLOBAL ANTIBODY DRUG CONJUGATES MARKET BY TECHNOLOGY, 2020-2027 ($ MILLION)
9. GLOBAL CLEAVABLE LINKER MARKET BY REGION, 2020-2027 ($ MILLION)
10. GLOBAL NON-CLEAVABLE LINKER MARKET BY REGION, 2020-2027 ($ MILLION)
11. GLOBAL ANTIBODY DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
12. NORTH AMERICAN ANTIBODY DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
13. NORTH AMERICAN ANTIBODY DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2020-2027 ($ MILLION)
14. NORTH AMERICAN ANTIBODY DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
15. EUROPEAN ANTIBODY DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
16. EUROPEAN ANTIBODY DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2020-2027 ($ MILLION)
17. EUROPEAN ANTIBODY DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
18. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
19. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2020-2027 ($ MILLION)
20. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
21. REST OF THE WORLD ANTIBODY DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
22. REST OF THE WORLD ANTIBODY DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2020-2027 ($ MILLION)
1. GLOBAL ANTIBODY DRUG CONJUGATES MARKET SHARE BY APPLICATION, 2020 VS 2027 (%)
2. GLOBAL ANTIBODY DRUG CONJUGATES MARKET SHARE BY TECHNOLOGY, 2020 VS 2027 (%)
3. GLOBAL ANTIBODY DRUG CONJUGATES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027, (%)
4. GLOBAL ANTIBODY DRUG CONJUGATES FOR BLOOD CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
5. GLOBAL ANTIBODY DRUG CONJUGATES FOR BREAST CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
6. GLOBAL ANTIBODY DRUG CONJUGATES FOR OVARIAN CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
7. GLOBAL ANTIBODY DRUG CONJUGATES FOR LUNG CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
8. GLOBAL ANTIBODY DRUG CONJUGATES FOR OTHER APPLICATION MARKET SHARE BY REGION, 2020 VS 2027 (%)
9. GLOBAL CLEAVABLE LINKER APPLICATIONS MARKET SHARE BY REGION, 2020 VS 2027 (%)
10. GLOBAL NON-CLEAVABLE LINKER MARKET SHARE BY REGION, 2020 VS 2027 (%)
11. US ANTIBODY DRUG CONJUGATES MARKET SIZE, 2020-2027 ($ MILLION)
12. CANADA MARKET ANTIBODY DRUG CONJUGATES MARKET SIZE, 2020-2027 ($ MILLION)
13. UK ANTIBODY DRUG CONJUGATES MARKET SIZE, 2020-2027 ($ MILLION)
14. GERMANY ANTIBODY DRUG CONJUGATES MARKET SIZE, 2020-2027 ($ MILLION)
15. SPAIN ANTIBODY DRUG CONJUGATES MARKET SIZE, 2020-2027 ($ MILLION)
16. FRANCE ANTIBODY DRUG CONJUGATES MARKET SIZE, 2020-2027 ($ MILLION)
17. ITALY ANTIBODY DRUG CONJUGATES MARKET SIZE, 2020-2027 ($ MILLION)
18. REST OF EUROPE ANTIBODY DRUG CONJUGATES MARKET SIZE, 2020-2027 ($ MILLION)
19. INDIA ANTIBODY DRUG CONJUGATES MARKET SIZE, 2020-2027 ($ MILLION)
20. CHINA ANTIBODY DRUG CONJUGATES MARKET SIZE, 2020-2027 ($ MILLION)
21. JAPAN ANTIBODY DRUG CONJUGATES MARKET SIZE, 2020-2027 ($ MILLION)
22. REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET SIZE, 2020-2027 ($ MILLION)
23. REST OF WORLD ANTIBODY DRUG CONJUGATES MARKET SIZE, 2020-2027 ($ MILLION)
